Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm LentiGlobin BB305 gene therapy study in transfusion-dependent beta-thalassemia without beta0/beta0 genotype
2015-004122-33Phase 3Completed
- Sponsor
- bluebird bio, Inc.
- Start
- May 2016
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of betibeglogene autotemcel in beta thalassemia, sponsored by bluebird bio, Inc. Primary endpoint: Efficacy endpoint. Started May 2016; status: completed.
02
Drugs
betibeglogene autotemcel
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2015-004122-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004122-33.